CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) (NCT06783309)
A Phase 1b/2a Double Blind, Placebo Controlled Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Efficacy of CNP-103 in Participants Ages 12-35 With Recent Onset Stage 3 Type 1 Diabetes
🩺 Plain-English Summary (8th-Grade Level)
This study is a Phase 1b/2a First-in-Human (FIH) clinical trial to assess the safety, tolerability, pharmacodynamics (PD), and efficacy of multiple ascending doses of CNP-103. The approximately 393-days study consists of a Screening Period (28 days), Treatment Period (90 days), and Post-Dose Evaluations (275 days).
Who can join: Review the eligibility criteria below.
Location: Wake Research - Tucson — Tucson, Arizona
Age range: 12 Years to 35 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (38 Sites)
Showing the first 25 of 38 sites.
- Wake Research - Tucson — Tucson, Arizona
- Liver Institute PLLC — Tucson, Arizona
- Hoag Memorial Hospital — Newport Beach, California
- Rady Children's Hospital San Diego — San Diego, California
- Diablo Clinical Research — Walnut Creek, California
- Barbara Davis Center for Childhood Diabetes — Aurora, Colorado
- Southwest General Healthcare Center — Fort Myers, Florida
- University of Florida — Gainesville, Florida
- Evolution Research Center — Hialeah, Florida
- University of Miami — Miami, Florida
- DY Professional Research Center — Miami, Florida
- University of South Florida — Tampa, Florida
- Atlanta Diabetes Association — Atlanta, Georgia
- Emory University — Atlanta, Georgia
- Children's Healthcare of Atlanta — Atlanta, Georgia
- Rocky Mountain Diabetes and Osteoporosis Center — Idaho Falls, Idaho
- Northwestern University — Chicago, Illinois
- Southern Illinois University School of Medicine — Springfield, Illinois
- Riley Hospital for Children- Indiana University — Indianapolis, Indiana
- Barry J. Reiner, MD, LLC — Baltimore, Maryland
- Joslin Diabetes Center — Boston, Massachusetts
- Embassy Research Network — Bloomfield Township, Michigan
- University of Minnesota — Minneapolis, Minnesota
- Children's Mercy Hospital — Kansas City, Missouri
- Washington University School of Medicine — St Louis, Missouri
📞 Contact the Study Coordinator
Phone: (317) 727-2551
Email: sslaughter@courpharma.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Type 1 Diabetes Mellitus
- Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D) — Chicago, Illinois
- Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes — Orange, California
- A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation — Chicago, Illinois
- Safety and Effectiveness of the Luna System in People With Type 1 Diabetes Mellitus — Walnut Creek, California
- Triple Therapy in T1DM — Williamsville, New York
- Clinical Phase II/III Trial of Ustekinumab to Treat Type 1 Diabetes (UST1D2) — Toronto, British Columbia
Explore by condition: All Type 1 Diabetes Mellitus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.